A new study suggests that mRNA technology from COVID-19 vaccines may enhance cancer treatments by improving patients' immune responses. Cancer patients who received mRNA vaccines like Pfizer or Moderna within 100 days of starting immunotherapy showed significantly better survival rates. The research followed over 1,000 patients with advanced lung or skin cancers, revealing a three-year survival rate of 55.7% for vaccinated patients compared to 30.8% for unvaccinated ones. Experts emphasize the need for caution, as the results may not definitively prove the vaccine's effectiveness without further randomized trials.